Pages

Wednesday, 18 December 2013

A Combination For Brain Cancer Research

----------------------------------------------
------------------------------------------------------------------

By Robert Sutter


Brain cancer research is going to focus tremendously on glioblastoma and for all of the right reasons. It is one of the most important names to consider when it comes to this particular field, which is something that you can figure out in due time. Seeing as how treatment may be troublesome to find, though, what if I were to tell you that a tandem of drugs can bring about certain degrees of success? I believe that it is a point to take into consideration when considering such a serious ailment.

US News and World Report posted an article about a potential treatment that could prove useful for the sake of treating glioblastoma. This is one point that should be looked into but you have to keep in mind that this condition stands as one of the most aggressive and common conditions seen in the brain. According to a study that was done by the University of Zurich, it is "virtually incurable." That being said, it seems like a two-pronged drug therapy approach could prove useful in the long term.

The study group at the university looked into this condition more so, utilizing mice in order to see how a drug combination could be utilized. The mice were given both a T cell-boosting protein - dubbed interleukin-12 - as well as a drug that would be able to block off the inhibitory function that is commonly associated with the T cell. Keep in mind that while only IL-12 could be put to use, it was determined that mice had a boosted survival rate of 25%. However, the results should not stop at this point, should they?

I do not know if this is necessarily the case, especially when you take into consideration that another drug came into play for the sake of brain cancer research. Basically, it would be utilized in order to block T cells that self-regulate. With this combination set in place, the survival rate was no longer at 25% but rather a more notable 80%. To say that this could prove to be a strong combination in the future would be an understatement. It is one that calls for the attention of various organizations, V-A-B-C included.

I think that, regardless of where this type of news goes, it's apparent that there are possibilities which exist. I believe that brain cancer research is all about finding out what works best and sticking with it or searching to find entirely unique drugs that can work alone or with others. The tandem that was referred to before is, in my mind, quite noteworthy. I have to believe that, in time, this will be able to develop and go on to become utilized in studies to come.




About the Author:



0 comments:

Post a Comment